Related Experiment Video

Updated: Jun 13, 2026

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry
11:39

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry

Published on: June 9, 2019

9.2K

Metabolomic profiling for predicting breast cancer treatment toxicities

Jennifer J Hu1,2, Alexandra N McMahon1, Yawen Lu1

  • 1Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Translational Cancer Research
|August 12, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Metabolomicsbreast cancer treatmentsneurologic and metabolic toxicities

More Related Videos

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

6.0K
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

644

Related Experiment Videos

Last Updated: Jun 13, 2026

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry
11:39

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry

Published on: June 9, 2019

9.2K
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

6.0K
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

644

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

BioMaster: Multi-agent system for automated bioinformatics analysis workflow.

Patterns (New York, N.Y.)·2026

gBOLD-CSF coupling as a noninvasive predictor of cognitive recovery after shunt surgery in Idiopathic normal pressure hydrocephalus.

European journal of radiology·2026

Yang-Xue-An-Tai Decoction Treats URSA by regulating the differentiation of proliferating decidual stromal cells through multiple targets.

Journal of ethnopharmacology·2026

HIV, nephrotoxic medications, and chronic kidney disease: Prevalence, risk factors, and mediation analyses among people with and without HIV enrolled in the Multicenter AIDS Cohort Study (MACS)/ Women's Interagency HIV Study (WIHS) combined cohort study.

PloS one·2026

Multi-ancestry transcriptome-wide association studies uncover insights into breast cancer genetics and biology.

Nature communications·2026

Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity.

Acta pharmaceutica Sinica. B·2026

Palmitoylation-related gene signature for immune subtyping, prognostic stratification, and immunotherapy guidance in hepatocellular carcinoma.

Translational cancer research·2026

In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity in ROR1-positive triple-negative breast cancer.

Translational cancer research·2026

Garcinoic acid promotes ferroptosis-associated growth inhibition in esophageal squamous cell carcinoma through an MDM2-associated mechanism.

Translational cancer research·2026

Prognostic value of gut microbiota-derived metabolites in non-small cell lung cancer: a retrospective cohort study of overall survival.

Translational cancer research·2026

Sequential HER2-targeted antibody-drug conjugate therapy for acquired resistance in a 55-year-old male kidney transplant recipient with metastatic urothelial carcinoma: a case report.

Translational cancer research·2026

A multi-omics integration of bulk and single-cell transcriptomics identifies and validates a 16-gene epithelial-mesenchymal transition prognostic signature in tongue squamous cell carcinoma.

Translational cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us